MX2019014078A - Inhibidor de urat1 para promover la excresion de acido urico. - Google Patents
Inhibidor de urat1 para promover la excresion de acido urico.Info
- Publication number
- MX2019014078A MX2019014078A MX2019014078A MX2019014078A MX2019014078A MX 2019014078 A MX2019014078 A MX 2019014078A MX 2019014078 A MX2019014078 A MX 2019014078A MX 2019014078 A MX2019014078 A MX 2019014078A MX 2019014078 A MX2019014078 A MX 2019014078A
- Authority
- MX
- Mexico
- Prior art keywords
- uric acid
- acid excretion
- compounds
- promoting uric
- urat1 inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
La presente invención pertenece al campo de la química medicinal. Se describe especificamente a una clase de inhibidores de URAT1 para aumentar la excreción de ácido úrico, que son compuestos representados por la estructura de fórmula (I) o sus sales farmacéuticamente aceptables. Los experimentos muestran que los compuestos proporcionados por la presente invención tienen un efecto inhibidor muy bueno sobre el transporte de ácido úrico por hURAT1 en células transfectadas con HEK293, y que dichos compuestos tienen una buena posibilidad de aplicación en el tratamiento de hiperuricemia o gota.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710386922 | 2017-05-26 | ||
PCT/CN2018/088400 WO2018214961A1 (zh) | 2017-05-26 | 2018-05-25 | 促尿酸排泄的urat1抑制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019014078A true MX2019014078A (es) | 2020-08-03 |
Family
ID=63352281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014078A MX2019014078A (es) | 2017-05-26 | 2018-05-25 | Inhibidor de urat1 para promover la excresion de acido urico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11597725B2 (es) |
EP (1) | EP3632904B1 (es) |
JP (1) | JP6915907B2 (es) |
KR (1) | KR102420892B1 (es) |
CN (1) | CN108484600B (es) |
CA (1) | CA3066680C (es) |
DK (1) | DK3632904T3 (es) |
ES (1) | ES2912941T3 (es) |
MX (1) | MX2019014078A (es) |
PL (1) | PL3632904T3 (es) |
WO (1) | WO2018214961A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111410654B (zh) * | 2019-01-19 | 2022-05-17 | 江苏新元素医药科技有限公司 | 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成 |
CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
JP2022537291A (ja) * | 2019-06-17 | 2022-08-25 | フォチョン・ファーマシューティカルズ・リミテッド | ヘテロ環式誘導体及びその使用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1565734A (en) * | 1977-05-03 | 1980-04-23 | Laroche Navarron Sa | Fused triazoles |
NZ193926A (en) * | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
AR042067A1 (es) * | 2002-11-27 | 2005-06-08 | Bayer Pharmaceuticals Corp | Derivados de anilinopirazol utiles en el tratamiento de la diabetes |
CA2630884A1 (en) * | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
US8735386B2 (en) * | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
US10005750B2 (en) * | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
GB201321743D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
CN106065010B (zh) * | 2015-04-23 | 2019-01-01 | 镇江新元素医药科技有限公司 | 用于治疗或预防高尿酸血症或痛风的化合物 |
SG11201802010QA (en) | 2015-09-10 | 2018-04-27 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | A group of compounds used for the treatment or prevention of hyperuricemia or gout |
CN106433229A (zh) * | 2016-08-29 | 2017-02-22 | 无锡双诚炭黑有限公司 | 油炉法炭黑反应装置及其反应方法 |
WO2018090921A1 (zh) * | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
CN108084186B (zh) * | 2016-11-16 | 2021-06-25 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
-
2018
- 2018-05-25 WO PCT/CN2018/088400 patent/WO2018214961A1/zh unknown
- 2018-05-25 DK DK18806684.9T patent/DK3632904T3/da active
- 2018-05-25 US US16/617,426 patent/US11597725B2/en active Active
- 2018-05-25 PL PL18806684.9T patent/PL3632904T3/pl unknown
- 2018-05-25 MX MX2019014078A patent/MX2019014078A/es unknown
- 2018-05-25 KR KR1020197038336A patent/KR102420892B1/ko active IP Right Grant
- 2018-05-25 JP JP2019565209A patent/JP6915907B2/ja active Active
- 2018-05-25 CA CA3066680A patent/CA3066680C/en active Active
- 2018-05-25 CN CN201810517139.1A patent/CN108484600B/zh active Active
- 2018-05-25 ES ES18806684T patent/ES2912941T3/es active Active
- 2018-05-25 EP EP18806684.9A patent/EP3632904B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR102420892B1 (ko) | 2022-07-14 |
WO2018214961A1 (zh) | 2018-11-29 |
KR20200011974A (ko) | 2020-02-04 |
CA3066680C (en) | 2022-04-12 |
US20200262832A1 (en) | 2020-08-20 |
EP3632904B1 (en) | 2022-04-20 |
CN108484600B (zh) | 2022-12-13 |
CA3066680A1 (en) | 2018-11-29 |
US11597725B2 (en) | 2023-03-07 |
CN108484600A (zh) | 2018-09-04 |
EP3632904A1 (en) | 2020-04-08 |
JP6915907B2 (ja) | 2021-08-04 |
EP3632904A4 (en) | 2021-03-03 |
JP2020521757A (ja) | 2020-07-27 |
ES2912941T3 (es) | 2022-05-30 |
DK3632904T3 (da) | 2022-07-25 |
PL3632904T3 (pl) | 2022-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY197564A (en) | Urat1 inhibitor and use thereof | |
MY195675A (en) | A Group of Compounds used for the Treatment or Prevention of Hyperuricemia or Gout | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
EA201891917A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
PH12017501160A1 (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
UA111382C2 (uk) | Інгібітори протеїнкінази | |
MD20160106A2 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
MX2018002889A (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
UA111861C2 (uk) | Ароматична гетероциклічна сполука дигідрокси | |
WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
MX2019014078A (es) | Inhibidor de urat1 para promover la excresion de acido urico. | |
EA201200651A1 (ru) | Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек | |
AU2015275507A8 (en) | Cyclic dipeptide-containing composition | |
NZ629898A (en) | Compositions and methods for inhibition of cathepsins | |
PH12016501461A1 (en) | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors | |
MX2017013880A (es) | Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos. | |
EA201400831A1 (ru) | Пиразолопиримидиниловые ингибиторы убиквитин-активирующего фермента | |
MX2017010429A (es) | Acido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilami no)-2-hidroximetil-2-metilpentanoico. | |
MX2017000522A (es) | Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde. | |
MA33848B1 (fr) | Dérivés sulfonamides hétérocycliques | |
UY37987A (es) | Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3- metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico. | |
EA201391820A1 (ru) | Гетероциклические сульфонамидные производные | |
CR20130522A (es) | Inhibidores de la péptido desformilasa | |
PH12016502223A1 (en) | Pyrazine derivatives |